Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
76 patients who received a ponatinib-based regimen, either as monotherapy or in combination with chemotherapy, for chronic myeloid leukemia in myeloid blast phase (CML-MBP).
I · Intervention 중재 / 시술
ponatinib as salvage (60% versus 27%, respectively; = 0
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
After ponatinib failure, outcomes were dismal (median OS: 3.9 months). Ponatinib-based regimens are effective in CML-MBP, especially when used as first therapy and in combination with chemotherapy, followed by HSCT.
We analyzed 76 patients who received a ponatinib-based regimen, either as monotherapy or in combination with chemotherapy, for chronic myeloid leukemia in myeloid blast phase (CML-MBP).
APA
Karrar O, Kantarjian H, et al. (2025). Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase.. Leukemia & lymphoma, 66(12), 2269-2276. https://doi.org/10.1080/10428194.2025.2542946
MLA
Karrar O, et al.. "Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase.." Leukemia & lymphoma, vol. 66, no. 12, 2025, pp. 2269-2276.
PMID
40782369 ↗
Abstract 한글 요약
We analyzed 76 patients who received a ponatinib-based regimen, either as monotherapy or in combination with chemotherapy, for chronic myeloid leukemia in myeloid blast phase (CML-MBP). The rate of morphological remission with or without count recovery (i.e. overall response rate [ORR]) was 49%. Patients who received a ponatinib-based regimen as their first therapy for CML-MBP had better ORR than those received ponatinib as salvage (60% versus 27%, respectively; = 0.006). ORR was also higher with ponatinib combination therapy than monotherapy (54% versus 29%, respectively; = 0.06). For the entire cohort, the median RFS and OS were 11.9 and 8.5 months, respectively. Responding patients who underwent allogeneic HSCT had superior outcomes to those who did not (2-year OS 79% versus 38%, respectively; = 0.05). After ponatinib failure, outcomes were dismal (median OS: 3.9 months). Ponatinib-based regimens are effective in CML-MBP, especially when used as first therapy and in combination with chemotherapy, followed by HSCT.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Pyridazines
- Imidazoles
- Male
- Female
- Middle Aged
- Blast Crisis
- Leukemia
- Myelogenous
- Chronic
- BCR-ABL Positive
- Adult
- Aged
- Treatment Outcome
- Antineoplastic Combined Chemotherapy Protocols
- Young Adult
- Hematopoietic Stem Cell Transplantation
- Recurrence
- Adolescent
- Protein Kinase Inhibitors
- Salvage Therapy
- Retrospective Studies
- Ponatinib
- chronic myeloid leukemia
… 외 3개
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.